[go: up one dir, main page]

PE20181352A1 - Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias - Google Patents

Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias

Info

Publication number
PE20181352A1
PE20181352A1 PE2018000402A PE2018000402A PE20181352A1 PE 20181352 A1 PE20181352 A1 PE 20181352A1 PE 2018000402 A PE2018000402 A PE 2018000402A PE 2018000402 A PE2018000402 A PE 2018000402A PE 20181352 A1 PE20181352 A1 PE 20181352A1
Authority
PE
Peru
Prior art keywords
compounds containing
heterocyclic compounds
useful compositions
mycobacterial infection
compositions against
Prior art date
Application number
PE2018000402A
Other languages
English (en)
Inventor
Marvin J Miller
Garrett Moraski
Original Assignee
Marvin J Miller
Garrett Moraski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marvin J Miller, Garrett Moraski filed Critical Marvin J Miller
Publication of PE20181352A1 publication Critical patent/PE20181352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta referido a compuestos de Formulas I y II, en donde cada X es N, C-R3 o C-R4, con la condicion de que no mas de dos X sean N; R1 y R2 son independientemente hidrogeno, grupo acilo, grupo alquenilo, grupo alcoxi, entre otros; tambien se refiere a una composicion farmaceutica que los comprenden y a un metodo para elaborarlos. Dichos compuestos son utiles como agentes eficaces contra infecciones por micobacterias
PE2018000402A 2015-09-17 2016-09-19 Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias PE20181352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220192P 2015-09-17 2015-09-17

Publications (1)

Publication Number Publication Date
PE20181352A1 true PE20181352A1 (es) 2018-08-22

Family

ID=58289763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000402A PE20181352A1 (es) 2015-09-17 2016-09-19 Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias

Country Status (13)

Country Link
US (2) US10919888B2 (es)
EP (1) EP3328382A4 (es)
JP (1) JP7055378B2 (es)
KR (1) KR20180053386A (es)
CN (1) CN108348510B (es)
AU (2) AU2016324598A1 (es)
BR (1) BR112018005208B1 (es)
CL (1) CL2018000688A1 (es)
IL (1) IL257743B (es)
MX (2) MX386078B (es)
PE (1) PE20181352A1 (es)
WO (1) WO2017049321A1 (es)
ZA (1) ZA201802323B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7055378B2 (ja) 2015-09-17 2022-04-18 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物
KR20210141778A (ko) 2016-06-07 2021-11-23 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EA201992253A1 (ru) 2017-03-23 2020-03-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
US20220071999A1 (en) * 2018-12-21 2022-03-10 University Of Notre Dame Du Lac Design and discovery of bd oxidase inhibitors for the treatment of mycobacterial diseases
EP3976031A4 (en) * 2019-05-28 2023-07-12 Shionogi & Co., Ltd MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A MYCOBACTERIAL INFECTION CHARACTERIZED BY THE COMBINATION OF A BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
TWI861208B (zh) * 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
CA3149868A1 (en) * 2019-09-13 2021-03-18 Jerome Emile Georges Guillemont Antibacterial compounds
JP2022549881A (ja) * 2019-09-26 2022-11-29 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
CA3211532A1 (en) * 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024206357A1 (en) * 2023-03-29 2024-10-03 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525602A1 (fr) 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
JPH0539205A (ja) 1990-12-21 1993-02-19 Takeda Chem Ind Ltd 農園芸用混合組成物
JP3026845B2 (ja) 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5464843A (en) 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
AU2223495A (en) 1994-04-15 1995-11-10 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
WO1996002542A1 (en) 1994-07-15 1996-02-01 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JPH09249666A (ja) 1996-01-12 1997-09-22 Takeda Chem Ind Ltd 三環性化合物の製造法およびその中間体
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
AUPP278498A0 (en) 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
BR0014078A (pt) 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP3729343B2 (ja) 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6552037B2 (en) 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US20050113576A1 (en) 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
CA2566184A1 (en) 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
CA2568850A1 (en) 2004-08-02 2006-02-16 Schwarz Pharma Ag Indolizine carboxamides and the aza and diaza derivatives thereof
ATE421962T1 (de) 2004-11-11 2009-02-15 Ferrer Int Imidazoä1,2-aüpyridinverbindungen, zusammensetzungen, anwendungen und verfahren, die damit in zusammenhang stehen
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20070032469A1 (en) 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
JP2009545518A (ja) 2006-05-18 2009-12-24 メルク エンド カムパニー インコーポレーテッド カンナビノイド−１受容体モジュレーターとしての置換エステル
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
JP2010505855A (ja) 2006-10-06 2010-02-25 アボット・ラボラトリーズ 新規なイミダゾチアゾール類およびイミダゾオキサゾール類
EP2112880A4 (en) 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
CN101631786A (zh) 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
US20080221093A1 (en) 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a heterocyclic moiety
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
CL2008001631A1 (es) 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
JP5412429B2 (ja) 2007-07-23 2014-02-12 クレストーン・インコーポレーテッド 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
RU2572616C2 (ru) 2008-02-01 2016-01-20 Оркид Рисерч Лабораториз Лимитед Новые гетероциклы
EP2300470A2 (en) 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
WO2009148961A2 (en) 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20120010188A1 (en) 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
CA2750635A1 (en) 2009-02-23 2010-08-26 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2432070T3 (es) 2009-02-24 2013-11-29 Respiratorius Ab Diazaheteroarilos broncodilatadores novedosos
EP2473504B1 (en) 2009-09-03 2015-02-25 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
BR112012010752B1 (pt) * 2009-11-05 2021-07-20 University Of Notre Dame Du Lac Compostos imidazo[1,2-a]piridina
CN102869661B (zh) * 2010-03-18 2015-08-05 韩国巴斯德研究所 抗感染化合物
CA2824350C (en) 2011-02-25 2019-07-02 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
KR102104125B1 (ko) * 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
EA201391769A1 (ru) * 2011-05-30 2014-04-30 Астеллас Фарма Инк. Имидазопиридиновые соединения
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
BR112015001201B1 (pt) * 2012-07-18 2022-02-22 University Of Notre Dame Du Lac Compostos anti-infecciosos 5,5-heteroaromáticos e composição
KR102151832B1 (ko) 2012-11-20 2020-09-03 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충제 화합물 및 조성물 및 이의 사용 방법
JP6056872B2 (ja) * 2012-11-30 2017-01-11 アステラス製薬株式会社 イミダゾピリジン化合物
HUE056198T2 (hu) * 2013-08-02 2022-02-28 Pasteur Institut Korea Fertõzés elleni vegyületek
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2017001660A1 (en) 2015-07-02 2017-01-05 Janssen Sciences Ireland Uc Antibacterial compounds
JP7055378B2 (ja) 2015-09-17 2022-04-18 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
MX2018015657A (es) 2016-06-16 2019-03-14 Janssen Sciences Ireland Unlimited Co Compuestos heterociclico como antibacterianos.
EP3266454A1 (en) 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Acc inhibitors for use in treating mycobacterial diseases
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN108159049B (zh) 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
WO2019175737A1 (en) 2018-03-12 2019-09-19 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN108358917B (zh) 2018-04-24 2020-06-19 北京市结核病胸部肿瘤研究所 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
CA3149868A1 (en) 2019-09-13 2021-03-18 Jerome Emile Georges Guillemont Antibacterial compounds

Also Published As

Publication number Publication date
EP3328382A1 (en) 2018-06-06
IL257743B (en) 2022-08-01
US20180265506A1 (en) 2018-09-20
CL2018000688A1 (es) 2018-11-16
ZA201802323B (en) 2019-01-30
WO2017049321A1 (en) 2017-03-23
JP2018532723A (ja) 2018-11-08
US20210198254A1 (en) 2021-07-01
EP3328382A4 (en) 2018-12-19
CN108348510A (zh) 2018-07-31
AU2016324598A1 (en) 2018-03-15
HK1252225A1 (zh) 2019-05-24
MX386078B (es) 2025-03-18
KR20180053386A (ko) 2018-05-21
MX2021000189A (es) 2021-03-25
MX2018003294A (es) 2019-04-25
IL257743A (en) 2018-04-30
RU2018111768A (ru) 2019-10-17
US11820767B2 (en) 2023-11-21
JP7055378B2 (ja) 2022-04-18
CA2998375A1 (en) 2017-03-23
BR112018005208A2 (pt) 2018-10-02
RU2018111768A3 (es) 2020-02-20
BR112018005208B1 (pt) 2023-12-12
US10919888B2 (en) 2021-02-16
CN108348510B (zh) 2022-01-04
AU2021203931A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
PE20181352A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
PE20191552A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3)
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
MX386927B (es) Composicion y metodo para el crecimiento del cabello.
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
MX2018009645A (es) Derivados haloalilamina indol y azaindol como inhibidores de lisil-oxidasas y sus usos.
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
CO2018001628A2 (es) Composiciones y formulaciones antimicrobianas
UY36651A (es) Compuestos antiestrogénicos
MX378386B (es) Composiciones antiirritantes sinérgicas de taurina y aloe.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
DOP2016000253A (es) Nuevos compuestos
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2